Stock UBM ULISSE BIOMED S.P.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Ulisse Biomed S.p.A.

Equities

UBM

IT0005451213

Market Closed - Borsa Italiana
Other stock markets
 09:14:59 03/05/2024 pm IST 		5-day change 1st Jan Change
1.18 EUR -4.07% Intraday chart for Ulisse Biomed S.p.A. -10.27% -28.70%
03/05 Ulysses Biomed reduces loss in 2023; NFP is positive AN
02/05 Mib positive; MPS updates annual high AN

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • Low profitability weakens the company.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
ULISSE BIOMED S.P.A. Stock Ulisse Biomed S.p.A.
-28.70% 27.42M -
MODERNA, INC. Stock Moderna, Inc.
+25.69% 47.9B
B-
LONZA GROUP AG Stock Lonza Group AG
+46.90% 41.42B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.7B
B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.92B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 25.55B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.27B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 12.15B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.14B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.99B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. UBM Stock
  4. Ratings Ulisse Biomed S.p.A.